CenterWatch

FDA Approved Drugs for Psychiatry/Psychology

Drugs Approved in 2014

Bunavail (buprenorphine and naloxone); BioDelivery Sciences; For the maintenance treatment of opioid dependence, Approved June 2014

Drugs Approved in 2013

Brintellix (vortioxetine); Takeda Pharmaceuticals USA; For the treatment of Major Depressive Disorder, Approved October 2013

Fetzima (levomilnacipran); Forest Laboratories; For the treatment of major depressive disorder, Approved July 2013

Zubsolv (buprenorphine and naloxone); Orexo AB; For the maintenance treatment of opioid dependence, Approved July 2013

Drugs Approved in 2012

Qsymia (phentermine + topiramate extended-release); Vivus; For the treatment of chronic weight management, Approved July 2012

Quillivant XR (methylphenidate hydrochloride); NextWave Pharmaceuticals; For the treatment of Attention Deficit Hyperactivity Disorder, Approved September 2012

Drugs Approved in 2011

Intermezzo (zolpidem tartrate sublingual tablet); Transcept Pharmaceuticals; For the treatment of insomnia, Approved November 2011

Viibryd (vilazodone hydrochloride); Clinical Data; For the treatment of major depressive disorder, Approved January 2011

Drugs Approved in 2010

Latuda (lurasidone); Sunovion; For the treatment of schizophrenia, Approved October 2010

Oleptro (trazodone hydrochloride); Labopharm; For the treatment of major depressive disorder, Approved February 2010

Vivitrol (naltrexone for extended-release injectable suspension); Alkermes; For the prevention of relapse to opioid dependence, Approved October 2010

Drugs Approved in 2009

Edluar (zolpidem tartrate); Orexo; For the treatment of insomnia, Approved March 2009

Fanapt (iloperidone); Vanda; For the treatment of schizophrenia, Approved May of 2009

Intuniv (guanfacine extended-release); Shire Pharmaceuticals; For the treatment of ADHD in children and adolescents, Approved September 2009

Saphris (asenapine); Schering-Plough; For the treatment of schizophrenia and manic or mixed bipolar 1 episodes, Approved August of 2009

Drugs Approved in 2008

Aplenzin (bupropion hydrobromide); Biovail Laboratories; For the treatment of major depressive disorder, Approved April 2008

Stavzor (valproic acid delayed release); Banner Pharmacaps; For the treatment of bipolar manic disorder, seizures and migraine headaches, Approved July 2008

Drugs Approved in 2007

Vyvanse (Lisdexamfetamine Dimesylate); New River; For the treatment of Attention-Deficit/Hyperactivity Disorder, Approved February 2007

Drugs Approved in 2006

Chantix (varenicline); Pfizer; For the treatment of nicotine addiction, Approved May 2006

Invega (paliperidone); Janssen Pharmaceuticals; For the treatment of schizophrenia, Approved December 2006

Vivitrol (naltrexone for extended-release injectable suspension); Alkermes; For the treatment of alcohol dependence, Approved April 2006

Drugs Approved in 2004

Cymbalta (duloxetine); Eli Lilly; For the treatment of major depressive disorder, Approved August 2004

Drugs Approved in 2002

Abilify (aripiprazole); Bristol-Myers Squibb, Otsuka America Pharmaceutical; Oral drug for the treatment of schizophrenia, Approved November 2002

Geodon (ziprasidone mesylate); Pfizer; To control agitated behavior and psychotic symptoms in schizophrenia patients, Approved June 2002

Lexapro (escitalopram oxalate); Forest Laboratories; An orally administered selective serotonin reuptake inhibitor useful for the treatment for major depressive disorder, Approved August 2002

Paxil CR (paroxetine hydrochloride); GlaxoSmithKline; Oral tablet for the treatment of depression and panic disorder, Approved February 2002

Ritalin LA (methylphenidate HCl); Novartis; Oral capsules for the treatment Attention-Deficit/Hyperactivity Disorder (ADHD), Approved June 2002

Strattera (atomoxetine HCl); Eli Lilly; For the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children, adolescents and adults., December 2002

Subutex/Suboxone (buprenorphine/naloxone); Reckitt Benckiser; Oral tablets for the treatment of opiate dependence, Approved October 2002

Zoloft (sertraline HCl); Pfizer; Oral tablets for the treatment of premenstrual dysphoric mood disorder (PMDD), Approved May 2002

Drugs Approved in 2001

Adderall XR; Shire Pharmaceuticals; Once-daily medication for the treatment of attention deficit/hyperactivity disorder (ADHD), Approved October 2001

Focalin (dexmethylphenidate HCl); Celgene; For the treatment of attention deficit hyperactivity disorder (ADHD), Approved November 2001

Metadate CD; Celltech Pharmaceuticals; Oral capsules for the treatment of attention deficit hyperactivity disorder, Approved April 2001

Prozac Weekly (fluoxetine HCl); Eli Lilly; For the treatment of depression, Approved February 2001

Remeron SolTab (mirtazapine); Organon; Orally disintegrating tablet for the treatment of depression, Approved January 2001

Ziprasidone (ziprasidone hydrochloride); Pfizer; Oral capsule for the treatment of schizophrenia, Approved February 2001

Drugs Approved in 2000

Concerta; Alza; For the treatment of Attention Deficit Hyperactivity Disorder, Approved August 2000

Drugs Approved in 1999

Effexor (venlafaxin HCL); Wyeth; Treatment for generalized anxiety disorder, Approved March 1999

Paxil CR (paroxetine hydrochloride); SmithKline Beecham; Treatment for depression, Approved March 1999

Sonata; American Home Products; Treatment fo insomnia, Approved August 1999

Drugs Approved in 1998

Celexa; Forest Laboratories; Treatment for depression, Approved July 1998

Clomipramine hydrochloride; Mylan Laboratories; Generic equivalent of Anafranil, Approved April 1998

Cylert; Abbott Laboratories; Treatment for Attention Deficit Disorder, Approved October 1998

Marplan Tablets; Roche; Treatment of Depression, Approved August 1998

Naltrexone Hydrochloride Tablets; Barr Laboratories; Generic equivalent of Revia, Approved May 1998

Prochlorperazine; IVAX; Generic equivalent of SmithKline Beecham's Compazine, Approved January 1998

Drugs Approved in 1997

Effexor XR (venlafaxin HCI); Wyeth; Treatment of depression, Approved October 1997

Generic Transdermal Nicotine Patch; Sano; Generic equivalent of Habitrol, Approved October 1997

LUVOX (fluvoxamine maleate); Solvay Pharmaceuticals, Pharmacia & Upjohn; Treatment for obsessive compulsive disorder (OCD) in children and adolescents, Approved April 1997

Seroquel (R) (quetiapine fumarate) Tablets; AstraZeneca; Treatment for schizophrenia, Approved September 1997

Trazadone 150mg; Teva Pharmaceutical; Generic equivalent of Desyrel 7, Approved May 1997

Zoloft (sertraline HCl); Pfizer; Treatment for panic disorder, Approved July 1997

Zoloft (sertraline HCl); Pfizer; Treatment of panic disorder in children ages 6-17, Approved October 1997

Zyban Sustained-Release Tablets; GlaxoSmithKline; Treatment for smoking cessation, Approved May 1997

Drugs Approved in 1996

Adderall (mixed salts of a single-entity amphetamine); Richwood Pharmaceutical; Treatment for attention-deficit/hyperactivity disorder, Supplemental NDA Approved February 1996

ARICEPT (donepezil hydrochloride); Eisai; Treatment for Alzheimer's Disease, Approved December 1996

Depakote (divalproex sodium); Abbott Laboratories; Treatment for migraine headaches, Approved March 1996

Lithobid (Lithium Carbonate); Solvay Pharmaceuticals; Treatment for manic depression, Approved January 1996

NicoDerm CQ; SmithKline Beecham, Hoechst Marion Roussel, Alza; Treatment for smoking cessation, Approved August 1996

Nicorette (nicotine polacrilex); SmithKline Beecham; Over-the-counter aid in smoking cessation, Approved February 1996

Nicotrol nasal spray; Pharmacia & Upjohn; Treatment for nicotine addiction, Approved March 1996

Nicotrol transdermal patch; McNeil Consumer Products; Treatment for smoking cessation, Approved July 1996

Paxil (paroxetine hydrochloride); SmithKline Beecham; Treatment for panic disorder, Approved May 1996

Redux (dexfenfluramine hydrochloride); Wyeth; Treatment for obesity, Approved May 1996

Remeron (Mirtazapine); Organon; Treatment for depression, Approved June 1996

Risperdal Oral Formulation; Janssen Pharmaceuticals; Treatment for schizophrenia, Approved July 1996

Zyprexa; Eli Lilly; Treatment of the symptoms of psychotic disorders, Approved September 1996